Chemotherapy Induced Myelosuppression Treatment Market

Chemotherapy-Induced Myelosuppression Treatment Market: Increasing Prescription of Chemo-Adjuvant Therapy for Cancer Management to Boost Growth: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

  • 2019-01-28
  • REP-GB-1364
  • 211 pages
  • PDF PPT EXCEL
Chemotherapy Induced Myelosuppression Treatment Market

An Incisive, In-depth Analysis on the Chemotherapy Induced Myelosuppression Treatment Market

This study offers a comprehensive, 360 degree analysis on the Chemotherapy Induced Myelosuppression Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Chemotherapy Induced Myelosuppression Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Top 3 Leading Manufacturers to Account for Majority of the Revenue Share

The chemotherapy-induced myelosuppression treatment market is dominated by the top 3 major manufacturers, which include Amgen Inc., Teva Pharmaceutical Industries Ltd. and Janssen Pharmaceutical NV. These manufacturers are competing on the basis of the new drug launched, improving geographical product footprints and the prices of products. The manufacturers in the chemotherapy-induced myelosuppression treatment market are focusing on the expansion of their product portfolios by launching different biosimilars to originator products in various regions.

Amgen Inc. holds a major share of the revenue of the global chemotherapy-induced myelosuppression treatment market. Amgen Inc. is the originator of various biologics and has held patents for various formulations. However, due to the recent patent expiry of various products, it is facing tremendous competition from the new biosimilars that have been introduced in the chemotherapy-induced myelosuppression treatment market by other manufacturers such as Janssen Pharmaceutical NV, Sandoz, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan NV and others. By undergoing partnerships and collaborations with regional medium as well as large businesses, the manufacturers of chemotherapy-induced myelosuppression treatment market are focusing on expanding their regional product footprint by launching new products as well as their existing portfolio in developed countries.

Early Diagnosis and Reduction in Cancer Mortality Driving Revenue Growth

Cancer is the second leading cause of deaths worldwide. According to the World Health Organization (WHO), the number of deaths due to cancer worldwide in 2015 was 8.8 million. However, according to recent SEER Cancer statistics, the worldwide cancer death rate fell by 26.0% during 1991 – 2015, which can be attributed to early diagnosis that subsequently leads to early treatment. The global availability of advanced treatment options, such as chemotherapy, radiotherapy & surgical procedures is also boosting the chemotherapy-induced myelosuppression treatment market. The early diagnosis of cancer has enhanced the treatment-seeking rate in the developed world and is slowly improving in developing world, which is, in turn, a major driver of the chemotherapy-induced myelosuppression treatment market. The chemotherapy-induced myelosuppression treatment holds significant potential for revenue generation in developing countries owing to improving treatment-seeking rates and improving product availability.

Approval of Biosimilars in Chemotherapy-Induced Myelosuppression Formulations

The patent expiry of various originator biologics in the chemotherapy-induced myelosuppression treatment market has created significant opportunity for other manufacturers in the chemotherapy-induced myelosuppression treatment market to launch the biosimilars for these products. Most of the patents in the chemotherapy-induced myelosuppression treatment market were held by Amgen Inc. However, several of them have expired in the past three to five years, i.e. from 2013 to 2018, which has led to the launch and approval of various biosimilars in the high revenue-generating chemotherapy-induced myelosuppression treatment markets such as North America and Europe. For example, the patent for Amegen Inc.’s Neulasta, a biologic used for the treatment of neutropenia, expired in 2015 in the U.S., following which Sandoz launched Zarxio, the first biosimilar in the U.S. Although the cost variation between originator formulations and biosimilars is only 15% to 20%, it can reduce the economic burden on patients. The growth of the chemotherapy-induced myelosuppression treatment market can be majorly attributed to the increasing availability of comparatively cost-effective biosimilars in the chemotherapy-induced myelosuppression treatment market.

Extensive Drug Pipeline Likely to Increase the Availability of Cost-Effective Products

Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market. Growing R&D expenditure by pharmaceutical industries for the various drugs used for chemotherapy-induced myelosuppression treatment is expected to boost the product pipeline. The presence of various clinical-stage pharmaceutical companies, which are focusing on the development of novel drugs for chemotherapy-induced myelosuppression treatment, is expected to be a major forecast impact factor.

Competitive Landscape

This section of the report features the profiles of the key players of the chemotherapy-induced myelosuppression treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include Novartis AG, Amgen Inc., Pfizer Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Myelo Therapeutics GmbH, Janssen Global Services, LLC (Johnson & Johnson), Mission Pharmacal Company, Partner Therapeutics, Inc. and Dova Pharmaceuticals.

The key manufacturers of chemotherapy-induced myelosuppression treatment are focusing on increasing their geographical footprints as well as launching new products to increase their revenue generation in the chemotherapy-induced myelosuppression treatment market.

Definition

Chemotherapy-Induced myelosuppression is defined as the decreased ability of the bone marrow to produce blood cells (WBC, RBC and platelets). It occurs most commonly in cancer patients as an adverse effect of chemotherapy drugs, especially in case of cancers that are located near the bone marrow or near large bones with cavities. Chemotherapy-induced myelosuppression can result in the decreased production of red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).

About the Report

The company conducted a research study on the chemotherapy-induced myelosuppression treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the chemotherapy-induced myelosuppression treatment market with insights on the prices, current trends and reimbursement scenario in the chemotherapy-induced myelosuppression treatment market.

Segmentation

The report offers a comprehensive taxonomy of the chemotherapy-induced myelosuppression treatment market based on the indication, drug class, and route of administration, distribution channel and region. By indication, the chemotherapy-induced myelosuppression treatment market is segmented into neutropenia, anaemia and thrombocytopenia. By drug class, the chemotherapy-induced myelosuppression treatment market is segmented into growth factors, erythropoietin stimulating agents, thrombopoietic agents, iron supplements and others. By route of administration, the chemotherapy-induced myelosuppression treatment market is segmented as oral and injectable. By distribution channel, the chemotherapy-induced myelosuppression treatment market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies and drug stores. The chemotherapy-induced myelosuppression treatment market has been analysed across the regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and the Middle East & Africa (MEA).

Additional Questions Answered

Some of the additional questions addressed in this report on the chemotherapy-induced myelosuppression treatment market:

  • What is the overall revenue generation potential of the chemotherapy-induced myelosuppression treatment market across the regions of Europe and Asia-Pacific?

  • Who are the key regional and global competitors? What are their portfolios in the chemotherapy-induced myelosuppression treatment market?

  • What are the major challenges influencing the growth of the chemotherapy-induced myelosuppression treatment market?

Research Methodology

The chemotherapy-induced myelosuppression treatment market has been estimated based on a supply-demand approach. The market was first calculated based on the epidemiology of myelosuppression in different regions/countries in the chemotherapy-induced myelosuppression treatment. Some of the other qualitative factors analysed include the awareness level and the availability of drugs for chemotherapy-induced myelosuppression treatment for different indications. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals and resourceful databases). The research study on the chemotherapy-induced myelosuppression treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the chemotherapy-induced myelosuppression treatment market. With this approach, the report on the chemotherapy-induced myelosuppression treatment market estimates the industry attractiveness of every major segment in the chemotherapy-induced myelosuppression treatment over the forecast period.

A recent market study published by the company “Chemotherapy-Induced Myelosuppression Treatment Market: Global Industry Analysis 20132017 & Opportunity Assessment 2018–2028” consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the chemotherapy-induced myelosuppression treatment market, the growth prospects of the market are obtained with maximum precision. The report features the unique and salient factors that are likely to significantly impact the development of the chemotherapy-induced myelosuppression treatment market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the chemotherapy-induced myelosuppression treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects of the chemotherapy-induced myelosuppression treatment market in the most comprehensive manner for the better understanding of readers.

Chapter 01 – Executive Summary

The report commences with the executive summary of the chemotherapy-induced myelosuppression treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the chemotherapy-induced myelosuppression treatment market.

Chapter 02 – Market Introduction

Readers can find the detailed taxonomy and the definition of the chemotherapy-induced myelosuppression treatment market in this chapter, which will help them understand the basic information about the chemotherapy-induced myelosuppression treatment market dynamics, supply chain, cost structure and pricing analysis. A list of key distributors and suppliers, as well as a list of key market participants is included in the report.

Chapter 03 – North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

This chapter includes a detailed analysis of the growth of the North America chemotherapy-induced myelosuppression treatment market along with a country-wise assessment that includes the U.S. and Canada. Readers can also find regional trends, regulations and market growth based on the end users and countries in North America.

Chapter 04 – Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

Readers can find detailed information about several factors, such as the pricing analysis and the regional trends, which are impacting the growth of the Latin America chemotherapy-induced myelosuppression treatment market. This chapter also includes the growth prospects of the chemotherapy-induced myelosuppression treatment market in the leading LATAM countries such as Brazil, Mexico, Argentina and the Rest of Latin America.

Chapter 05 – Western Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

Important growth prospects of the chemotherapy-induced myelosuppression treatment market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy and Rest of Western Europe, are included in this chapter.

Chapter 06 – Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

Important growth prospects of the chemotherapy-induced myelosuppression treatment market based on its product types and applications in several countries, such as Russia, Poland and the Rest of Eastern Europe, are included in this chapter.

Chapter 07 – APEJ Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

In this chapter, China, India, ASEAN, Australia and New Zealand are the leading countries in the APEJ region, which are the prime subjects of assessment to obtain the growth prospects of the APEJ chemotherapy-induced myelosuppression treatment market. Readers can find detailed information about the growth parameters of the APEJ chemotherapy-induced myelosuppression treatment market during the period 2018–2028.

Chapter 08 – Japan Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

Readers can find important factors that can significantly impact the growth of the chemotherapy-induced myelosuppression treatment market in Japan during the forecast period based on the market segmentation.

Chapter 09 – MEA Chemotherapy-Induced Myelosuppression Treatment Market Analysis 20132017 & Opportunity Assessment 20182028

This chapter provides information about how the chemotherapy-induced myelosuppression treatment market will grow in the major countries in the MEA region, such as GCC Countries, South Africa and the rest of MEA, during the period 2018–2028.

Chapter 10 – Competition Landscape, Company Share and Company Profiles

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the chemotherapy-induced myelosuppression treatment market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview and recent company developments. Some of the market players featured in the report are Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG, Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson) and Partner Therapeutics, Inc.

Chapter 11 – Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 - 2017 & Opportunity Assessment 2018 - 2028, By Drug Class

Based on the type, the chemotherapy-induced myelosuppression treatment market is segmented into growth factors, erythropoietin stimulating agents, thrombopoietic agents, iron supplements and others. In this chapter, readers can find information about the key trends and developments in the chemotherapy-induced myelosuppression treatment market and market attractiveness analysis based on the type.

Chapter 12 – Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 - 2017 & Opportunity Assessment 2018 - 2028 By Indication

Based on the indication, the chemotherapy-induced myelosuppression treatment market is segmented into neutropenia, anaemia and thrombocytopenia. In this chapter, readers can find information about the key trends and developments in the chemotherapy-induced myelosuppression treatment market and market attractive analysis based on indication.

Chapter 13 – Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 - 2017 & Opportunity Assessment 2018 - 2028, By Route of Administration

Based on the route of administration, the chemotherapy-induced myelosuppression treatment market is segmented into oral and injectables. In this chapter, readers can find information about the key trends and developments in the chemotherapy-induced myelosuppression treatment market and market attractive analysis.

Chapter 14 – Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 - 2017 & Opportunity Assessment 2018 - 2028, By Distribution Channel

Based on the distribution channel, the chemotherapy-induced myelosuppression treatment market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. In this chapter, readers can find information about the key trends and developments in the chemotherapy-induced myelosuppression treatment market and market attractive analysis based on the distribution channel for each region.

Chapter 15 – Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013 - 2017 & Opportunity Assessment 2018 - 2028, By Region

This chapter explains how the chemotherapy-induced myelosuppression treatment market will grow across various geographic regions, such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa (MEA).

Chapter 16 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the chemotherapy-induced myelosuppression treatment report.

Chapter 17 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the chemotherapy-induced myelosuppression treatment market.

Chemotherapy Induced Myelosuppression Treatment Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology